BTCC / BTCC Square / Global Cryptocurrency /
Hims & Hers Stock Rebounds 33% from Lows on Wegovy Deal With Novo Nordisk

Hims & Hers Stock Rebounds 33% from Lows on Wegovy Deal With Novo Nordisk

Global Cryptocurrency
Release Time:
2025-04-29 19:17:01
0

Hims & Hers Health stock has surged 26% following a strategic partnership with Novo Nordisk for the weight-loss drug Wegovy. The digital health company is capitalizing on rising demand by offering a bundled package starting at $599, fueling investor optimism.

The stock’s near-triple performance over the past year reflects growing confidence in telehealth solutions. Upcoming Q1 earnings are anticipated to shed light on whether this momentum can sustain the early 2025 technical rebound.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users